Related Experiment Video
Updated: Jun 6, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
Published on: December 19, 2025
PCA3: from basic molecular science to the clinical lab
John R Day1, Matthias Jost, Mark A Reynolds
1Gen-Probe Incorporated, San Diego, CA, United States. John.Day@gen-probe.com
Prostate cancer gene 3 (PCA3) shows promise as a biomarker for diagnosing prostate cancer. This urine test, when used with PSA levels, improves diagnostic accuracy and aids clinical decisions for at-risk patients.
Area of Science:
- Oncology
- Molecular Diagnostics
- Urology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Serum prostate specific antigen (PSA) testing improves early detection but has low specificity, leading to false positives and unnecessary biopsies.
- Novel biomarkers are needed to enhance prostate cancer diagnosis.
Purpose of the Study:
- To evaluate the utility of prostate cancer gene 3 (PCA3) as a biomarker for prostate cancer diagnosis.
- To assess the potential of PCA3 in combination with existing clinical information for improving diagnostic accuracy.
Main Methods:
- Development of a non-invasive urine test for PCA3.
- Analysis of PCA3 expression in prostate cancer versus benign tissue.
- Clinical studies assessing PCA3's diagnostic and potential prognostic value.
Main Results:
- PCA3 is a noncoding RNA significantly over-expressed in prostate cancer tissue.
- The urine-based PCA3 test demonstrates utility in diagnosing prostate cancer.
- Combining PCA3 with PSA and clinical data enhances diagnostic accuracy.
Conclusions:
- PCA3 is a valuable biomarker for prostate cancer detection.
- The PCA3 urine test aids in making more informed clinical decisions for patients at risk.
- Further research may explore PCA3's prognostic capabilities.
More Related Videos
08:38Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay (PCA) in Living Cells
Published on: March 3, 2015
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
Related Concept Videos
GPCR Desensitization
IP3/DAG Signaling Pathway
cAMP-dependent Protein Kinase Pathways
PCR - Polymerase Chain Reaction
GPCRs Regulate Adenylyl Cylase Activity
Two...
Rapid Identification of Pathogens